MLTX — MOONLAKE IMMUNOTHERAPEUTICS

Ownership history in Engineers Gate Manager LP  ·  2 quarters on record

This page tracks every 13F SEC filing in which Engineers Gate Manager LP reported a position in MOONLAKE IMMUNOTHERAPEUTICS (MLTX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
0.01% (2024 Q2)
Avg. % of fund
0.01%
First filed
2024 Q2
Last filed
2025 Q3
Quarters held
2
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 ADDED 58,810 +46,541 +379.3% 0.00% $422K $7.17
2024 Q2 INITIATED 12,269 — — 0.01% $539K —
% of Fund (quarterly)    MLTX price (monthly, adj. close)

Other funds also holding MLTX

As of 2025 Q4 — sorted by position size

BVF INC/IL 3Y 7Y 8.76% Lion Point Capital, LP 3Y 7Y 4.6% Cormorant Asset Management, LP 3Y 7Y 2.65% Logos Global Management LP 3Y 1.39% Deep Track Capital, LP 3Y 1.08% Vivo Capital, LLC 3Y 7Y 0.85% STEMPOINT CAPITAL LP 0.79% Eagle Health Investments LP 3Y 0.54% ACUTA CAPITAL PARTNERS, LLC 3Y 7Y 0.53% Rhenman & Partners Asset Management AB 3Y 7Y 0.45%
← Back to Engineers Gate Manager LP Holdings